Objective: Prosthetic grafts used for lower extremity revascularization and dialysis access fail because of hyperplastic stenosis and thrombosis. Graft surveillance is advocated to monitor function; however, graft failure can occur between episodic examinations. An innovative sensor with wireless, microchip technology allows automated surveillance with assessment of graft function using a "cloud"-based algorithm. We performed proof-of-concept experiments with in vitro and in vivo models to assess the feasibility such a real-time graft surveillance system.
preservation. 1 Intervention for the "failing graft" is likely to be performed with endovascular techniques, whereas occluded grafts commonly require more complex reoperative procedures with a higher morbidity and mortality rate. 2 Graft surveillance based solely on clinical evaluation is recognized to miss critical stenoses, especially when the bypass was originally performed for critical limb ischemia. 2 Prosthetic graft failure and thrombosis can occur without premonitory clinical symptoms or signs, often in the interval between scheduled follow-up examinations. The addition of duplex ultrasound to a surveillance program improves the performance of vein grafts, [3] [4] [5] with sparse data regarding the surveillance of prosthetic grafts. This report describes preliminary results of a self-monitoring graft system consisting of an expanded polytetrafluoroethylene (ePTFE) graft, a piezoelectric microsensor, microelectronics with battery, and a remote processor. This graft system has the ability to continuously monitor hemodynamic data with wireless transmission, thereby communicating information in real time to a remote processor for data collection and analysis. This series of experiments assessed the ability of the graft-sensor system to accurately assess graft flow in vitro and in vivo through soft tissue over a time interval.
METHODS
A series of in vitro and in vivo experiments were performed to evaluate a "smart graft" system consisting of a piezoelectric microsensor incorporated into a standard expanded ePTFE graft with associated microelectronics, an external monitor, and a remote processor. The sensor consisted of two piezoelectric polyvinylidene fluoride (PVDF) sensors 28 mm in thickness. This material was circumferentially wrapped around the extraluminal surface of ePTFE grafts. The sensors were then encapsulated in Mylar (Dupont Tejjin Films, Tokyo, Japan) and attached to the ePTFE using an acrylic adhesive. An oscilloscope (model DSOX2004; Keysight, Santa Clara, Calif) was used in conjunction with MATLAB signal processing software (MathWorks, Natick, Mass) for data collection and storage by a remote central processing unit (Lenovo, Morrisville, NC).
In vitro studies. In vitro studies were performed to demonstrate the ability of the graft-sensor system to generate and quantify a flow signal from the ePTFE graft in the context of variable flow rates and degrees of stenosis introduced into the system. An in vitro flow model was constructed to enable modular testing of the ePTFE-piezoelectric sensor configuration. The flow apparatus was assembled as a recirculating pulsatile system to mimic arterial flow. Deionized water was used as the fluid medium and circulated through polyurethane tubing from a reservoir through an 8-mm ePTFE graft and back to the reservoir. The pump was a Harvard Apparatus (Holliston, Mass) pulsatile-flow pump, which was varied from 50 to 90 beats/min with a systolicto-diastolic ratio of 40:60. The water reservoir was placed at a specific height above the flow system to approximate a vascular flow resistance of w40 mm Hg. The ePTFE graft sensor was embedded in ballistic gelatin to mimic the properties of surrounding and encapsulating human tissue. The system was tuned so that flow through the graft was w400 mL/min to be consistent with reported values of flow through a human femoral artery. 6 Flow signals were obtained from the graft sensor at variable beats/min and stroke volumes. Different levels of stenosis were then introduced into the flow system. To create stenosis in the flow model, three-dimensional printing was used to produce different degrees of narrowing in the system tubing. The degree of stenosis was reported as the percentage reduction in the diameter compared with the diameter of the original system tubing. Owing to limitations in the three-dimensional fabrication process, the minimal degree of stenosis that could be tested was 25%. Levels of stenosis were then tested at 5% increments to a maximum of 80% stenosis by interposition of the tubing segments of diminished diameters.
Signal values were obtained by wireless transmission from the piezoelectric sensor to determine the ability of the system to obtain flow data and then assess any relationship between sensor output and degree of stenosis. To obtain the signal values, the piezoelectric sensors were sampled by an oscilloscope at 5 kHz. An external central processing unit running MATLAB controlled the oscilloscope. MATLAB was then used to process and analyze the collected data. Flow signal acquisition was tested with system stenosis at various distances up to 20 cm proximal and distal to the PVDF sensor. When the sensor was located near the center of the graft, stenoses were simulated within the graft and at each end of the graft in the area of the anastomoses.
In vivo studies. In vivo experiments were performed in an ovine carotid artery model to test the system's ability to enable wireless transmission of flow-related data through living tissue from an implanted graft to the processor and to maintain signal transmission beyond the time of immediate implantation. When implanted in vivo, a silicone adhesive was used to attach the 2-cm-long PVDF sensor to the 20-cm section of ePTFE with a Parylene-C coating (Specialty Coating Systems, Indianapolis, Ind) to ensure stability for implantation.
To enable wireless communication, the sensor transmitted signals by a microelectronic circuit containing an encapsulated board with a Bluetooth (Bluetooth SIG, Inc, Kirkland, Wash) microcontroller chip (Texas Instruments, Dallas, Tex). Firmware and mobile applications were modified to enable wireless data collection from the implanted chip using a standard smartphone or tablet. The mobile device (smartphone, tablet) was then used to upload the raw data to a remote server for data processing. The transmission process occurred via the following five steps:
1. The Bluetooth microcontroller chip pairs with a custom mobile application on the mobile device. 2. After pairing, the mobile application requests data from the implanted microcontroller. 3. The microcontroller collects and transmits the data to the mobile application. 4. The mobile application writes a data file containing this data. 5. The data file is uploaded to a remote server location.
A carotid-to-carotid bypass was performed in four sheep with end-to-side anastomoses and interval ligation of the native carotid artery (institutional review board approval was obtained through ARC study proposal 1383 with animals cared for in compliance with ACUC requirements and the Guide for the Care and Use of Laboratory Animals). Completion arteriograms were obtained after each bypass to assess graftsensor configuration and confirm patency. The animals were recovered without complication.
The graft sensor was interrogated daily for the 30-day study interval. After 30 days, the animals were returned for final device evaluation and euthanasia with harvest of the implanted graft. Arteriograms were obtained before euthanasia to assess graft-sensor anatomy and patency. During harvest and before euthanasia, a transonic ultrasound flowmeter was attached to the graft so that simultaneous flowmeter and wireless graft-sensor measurements could be obtained for comparison. The flowmeter and transmitted sensor data were overlayed in postprocessing to enable precise comparison of the data signals.
Histopathology was performed on harvested graft segments (CVPath, Gaithersburg, Md). Digital photographs (Canon Rebel XSi; Canon, Melville, NY) were taken of the explanted tissue containing the device. The margins of each tissue block containing the device were marked with tissue dye for localization. High-contrast digitalbased radiographs (Model LX-60; Faxitron X-ray Corp, Tucson, Ariz) of the graft segments were acquired to locate the exact position of the device components for precise histopathologic analysis. A segment of the ePTFE conduit with the sensor was processed for plastic embedding along with the proximal and distal anastomotic sites bisected longitudinally. The sensor and both anastomotic sites were processed in a graded series of alcohols and xylenes and then embedded in Spurr's resin. A single block from each region was cut and ground to a thickness of w 66 to 120 mm using EXAKT Linear Grinding technology (EXAKT Technologies, Inc, Oklahoma City, Okla).
After surface grinding, histologic sections were stained with hematoxylin and eosin before evaluation by light microscopy. Inflammation was evaluated as minimal (<20 inflammatory cells/high-power field 
RESULTS
In vitro studies. Flow signals were reproducibly obtained from the graft sensor at varying flow parameters. The graft sensor system was able to detect and transmit flow signals in vitro corresponding to flow rates within the graft. The flow pump apparatus rate was varied to approximate a range of 50 to 90 beats/min in the pulsatile system with a corresponding increase in sensor output (Fig 1, A) . Stroke volume was also varied in the pulsatile flow system from 20 mL/stroke to 60 mL/stroke with reproducible signal output. Signal output and acoustic frequency that reflects acoustic energy generated by the signal varied with the degree of stenosis introduced in the flow system (Fig 1, B) . A proprietary parameter developed from multiple signal metrics regarding piezoelectric deformation, acoustic frequency, and frequency shift allowed a direct correlation with degree of stenosis. This proprietary parameter is related to acoustic energy, and was developed partially based on principles of phonoangiography. [7] [8] [9] This proprietary parameter is based on various parameters that indicate the level of acoustic energy present in the signal. This signal parameter showed that microsensor signal output correlated reliably with the degree of in vitro stenosis independent of the distance between the microsensor and area of stenosis (Fig 2) . The wireless signal also provided a direct correlation with location of the stenosis as proximal or distal to the graft microsensor (Fig 3) .
In vivo studies. The graft-sensor system was able to wirelessly monitor the flow in the ePTFE grafts at a remote location during the entire postoperative period in all animals. All graft sensors and anastomoses were widely patent at 30 days, with no sign of stenosis on arteriography before euthanasia. The microsensor transmitted data from the graft by wireless transmission at the time of implantation and through the healing soft tissue during the entire 30-day postoperative period. During this interval, data acquisition was obtained daily and successfully processed to monitor the status of flow within all grafts during the entire length of the study period.
Signal analysis confirmed that the character of the transmitted microsensor signal was maintained after 30 days in vivo and similar to the signals obtained at the initial implantation. There was no deterioration of the signal or the ability to acquire and process the data (Fig 4) . At euthanasia, the overlayer signal output waveforms obtained directly from a transonic ultrasound flow probe and wirelessly from the graft sensor revealed a direct correlation (Pearson product-moment correlation coefficient ¼ 0.61) between the microsensor signal output and the directly measured flow (Fig 5) .
Histopathology. At euthanasia, the graft-sensor conduits were explanted en bloc after intraoperative arteriography. The arteriograms confirmed graft patency, with no luminal irregularity in the area of the sensor unit (Fig 6) . There were no wound infections and no incisional dehiscence. The grafts and device components were all securely embedded in moderately dense connective Composite signal parameter generated from sensor output data that reliably identifies the degree of stenosis. tissue. Histopathologic analysis of the implanted devices and surrounding tissue confirmed that the microsensor continued to be apposed to the ePTFE (Fig 7) . The tissue reaction adjacent to the microsensor consisted of a minimal fibrous capsule with mild lymphohistiocytic infiltration. The luminal surface of the ePTFE in the area of the sensor was covered by a thin layer of fibrin with an overlying monolayer of endothelial cells. The ePTFE at the anastomotic site was also covered with a thin layer of neointima and vascular smooth muscle cells in a proteoglycan matrix. Luminal coverage of nonanastomotic ePTFE was variable, consisting of a thin layer of fibrin, minimal endothelium, and episodic mature vascular smooth muscle cells. The external, abluminal surface of the ePTFE graft showed lymphohistiocytic inflammation with a few scattered giant cells and rare acute inflammatory cells. This reaction was no different in the area of the microsensor compared with the abluminal surface of the remainder of the ePTFE conduit.
DISCUSSION
Prosthetic grafts are considered as a conduit for lower extremity bypass based on the patient's arterial anatomy, medical comorbidities, and availability of autogenous tissue. Despite technologic advances leading to improved performance, 10 prosthetic graft failure continues to occur owing to the development of myointimal hyperplasia or acceleration of atherosclerosis in the proximal or distal arterial bed. 11 The development of a hemodynamically significant stenosis before graft thrombosis has been termed a "failing graft." 12 Flow in a failing graft is hemodynamically compromised but may not result in overt clinical signs or symptoms, especially in patients initially treated for critical limb ischemia. Therefore, clinical evaluation alone, even with measurement of the ankle-brachial index may not identify such a failing graft.
2,13
In current practice, duplex ultrasound assessment has been added to surveillance protocols perioperatively and at intervals such as 3, 6, and 12 months, and annually. Ultrasound imaging identifies the threatened graft using physiologic criteria such as peak systolic velocity measurements (>300-350 cm/s), velocity ratio (>3.5-4.0), and graft flow velocity (<40 cm/s) guided by B mode images. However, systemic hemodynamic fluctuations, technical variability, and the episodic nature of the examination can affect the ability of ultrasound protocols to accurately predict impending graft failure.
Graft failure often results in a significant increase in symptom severity and possible limb loss. 14 Detection of the failing graft is important because the management of thrombosed grafts is often more complex than procedures required before complete graft occlusion. A failing graft can often be managed with endovascular techniques or more simplified surgical procedures, such as local revision with patch angioplasty, resulting in enhanced secondary patency and enhanced limb preservation. Performing a secondary bypass after graft thrombosis is technically more complex, with an increased perioperative morbidity and mortality. Therefore, most vascular surgical practices have incorporated graft surveillance programs to detect the failing graft and intervene early enough to improve graft function and secondary patency of the vascular reconstruction. 15 Unfortunately, duplex ultrasound protocols fail to detect thrombotic events before vein graft occlusion despite such programs. 13 The benefit of graft surveillance is even less well documented for prosthetic grafts, reflecting a continued need for improved surveillance technologies. However, Sanchez et al 16 concluded that prosthetic graft surveillance allows detection of hemodynamically threatening lesions before thrombosis and enhances graft function because patency and limb preservation were improved by treating failing PTFE grafts compared with treating grafts that had progressed to occlusion. A smaller study from Sweden randomized patients between clinical surveillance and surveillance that included duplex ultrasound evaluation. Although only 40 of the grafts in the trial were prosthetic, the authors noted improved assisted primary and secondary patency in the group with regular duplex ultrasound surveillance. 3 More recently, a combined experience from Boston and The Netherlands found ultrasound surveillance was effective in leading to a reduction in amputation and cost. 17 The piezoelectric effect was discovered by Pierre Curie in 1880 as the ability to assess changes in acceleration, pressure, force, and temperature through conversion to an electric charge for measurement. When exposed to mechanical stress, piezoelectric polymers develop electrical surface charges that generate a measurable voltage by appropriate electrodes. 18 PVDF is a particularly thin, light, and durable piezoelectric polymer with a high fidelity across a broad range of generated frequencies. This polymer also demonstrates high efficiency in the conversion of mechanical energy into electrical signals and has been used to sense biomedical data such as heart rate and respiration. 19 Piezoelectric materials have been used to evaluate graft flow in an animal model, demonstrating a correlation between an electromagnetic flowmeter Histopathologic analysis of an explanted sensor shows the microsensor to be apposed to the expanded polytetrafluoroethylene (ePTFE) conduit (sensor arrow) with minimal tissue reaction adjacent to the microsensor (arrow). The ligated common carotid artery (CCA) is noted to be thrombosed (CCA arrow).
and the piezoelectric sensor for acutely at the time of implantation of a prosthetic graft. 20 However, questions remained regarding the clinical utility of sensor transmission and signal acquisition as well as the ability of the piezoelectric material to function beyond the time of immediate implantation. Moreover, the advances in technology that have resulted over the past two decades from mobile devices and "the internet of things" have helped enable miniaturization of the system described in this work compared with the one described by Gupta et al. 20 The current set of experiments validated the concept of using a piezoelectric microsensor, microelectronics, and wireless communication to monitor information used to assess prosthetic graft function. The piezoelectric sensor incorporated into a prosthetic ePTFE graft was able to evaluate flow in both in vitro and in vivo models. The experiments demonstrated the ability of the piezoelectric microsensor to detect characteristic flow patterns in the graft that correlated with degrees of stenosis as created in the model. When degrees of stenosis were introduced in the in vitro flow models, the microsensor system was able to accurately differentiate these degrees of stenosis based on the collected signals.
In vivo experiments confirmed the system's ability to enable wireless transmission of flow-related data through living tissue from an implanted graft to the processor and to maintain signal transmission beyond the time of immediate implantation. A critical aspect of this demonstration ensured that wireless, remote signal transmission was possible without compromising graft function and patency. These data can be transmitted through the skin and soft tissue per the "cloud" to a remote location for data collection and analysis. The in vivo model demonstrated continued data collection over a 30-day period obtained through a closed incision and soft tissue. Signals were transmitted during the entire study period in a wireless manner through cell phone technology to the cloud to a subsequent processor and data collection system, without deterioration or signal loss.
Histologic analysis demonstrated that the sensor remained intact and apposed to the ePTFE graft without an effect on soft tissue healing. A slight increase in fibrous tissue was noted near the area of the graft with the device; however, the cellular components of the healing response were no different compared with the remaining graft area. The sensor and microelectronic components did not affect the luminal or surrounding soft tissue healing response. The luminal surface of the ePTFE near the sensor and microelectronics was not appreciably different from the surface in the remainder of the graft segments studied. A thin layer of fibrin with an overlying monolayer of endothelial cells covered the luminal surface with a thin layer of neointima and vascular smooth muscle cells in a proteoglycan matrix at the anastomotic areas. The results of this set of experiments hold promise for the development of a clinically useful system with the ability to monitor graft function in the setting of lower extremity bypass and possibly dialysis access to improve clinical outcomes.
CONCLUSIONS
This set of initial in vitro and in vivo experiments demonstrates the ability of a microsensor system to continuously monitor hemodynamic parameters reflecting graft function using wireless data transmission to a remote monitor. This system shows promise to deliver real-time data analyzed by cloud-based algorithms that would alert the clinician of a change in graft function or the development of stenosis for further diagnostic study or intervention before graft failure. The future study of this system will be directed toward determining its long-term monitoring capabilities, the adaptation of this system to vein grafts, and incorporation of this system into a clinical workflow. 
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DISCUSSION
Dr Joseph Mills (Houston, Tex). A "smart graft" system was evaluated consisting of a prosthetic graft, microelectronics (comprising a piezoelectric sensor, battery, and microprocessor), external monitor, and remote processor. The sensor was able to capture and transmit data from the graft by wireless transmission at implantation and through the healing soft tissue during the 30-day postoperative period. Theoretically the data could be pinged to a Health Insurance Portability and Accountability Act-compliant cloud and then to the surgeon.
Dr Neville and colleagues have set their sights on a laudable goal. A smart graft. Remote monitoring. Reduced patient visits. Minimally invasive, innovative, high-tech. A smart graft just sounds sexy. I confess over the years to have put in my fair share of dumb grafts; they just weren't smart enough to remain patent.
What do we know about graft failure? Two concepts are important here.
The first is the term "failing graft," attributed to Frank Veith, who identified a small number of patent but threatened grafts in patients subjected to arteriography with recurrent ischemia after a previous bypass.
The second concept is thrombotic threshold velocity: vein grafts are tolerant of low-flow states, prosthetic grafts less so. In the mid-1980s duplex graft surveillance was developed by Bandyk and others, and with the original black and white scanners, a cutoff peak systolic velocity of 45 cm/s was suggested as indicating a lowflow threatened graft.
Many groups, including ours at Wilford Hall and in Arizona, developed criteria for the graft-threatening stenosis that were improved by the addition of colorflow imaging. Surveillance is still widely practiced and very likely of benefit for vein grafts (albeit still debated) but of no accepted benefit for prosthetic grafts, stents, and percutaneous angioplasty sites? Why? Do we really know why some prosthetic grafts with stenosis occlude suddenly, others limp along for quite a while and remain patent, and others occlude without severe underlying stenosis. For example, 8-mm prosthetic femoralpopliteal prosthetic grafts in prospective studies have exhibited superior patency to 6-mm prosthetic grafts, yet their flow velocities are significantly lower, often <25 to 30 cm/s.
Is the premise for this device correct? When we first started doing graft surveillance without color-flow imaging on deeply tunneled vein grafts 30 years ago, we initially only checked a few sites in the graft and looked for a threshold low velocity. That approach actually worked well for vein grafts. With the advent of color, we found all types of flow disturbances in vein grafts and had to develop criteria for intervention. Basically severe, not moderate stenosis with or without reduced anklebrachial index; peak systolic velocity >350 to 400 cm/s and velocity ratio >4.0 were highly predictive of vein graft failure. Similar criteria for prosthetic grafts, however, are lacking. In addition, randomized trials of duplex surveillance and prophylactic reintervention for arteriovenous accesses either show no benefit or marginal benefit.
I This technology holds the potential for us to learn much about the time course and mechanisms of graft failure. These sensors could likely also be incorporated into stents and stent grafts. However, widespread clinical use will likely depend on how predictive the data are of a failing graft and how the system is designed to respond to the plethora of data that is generated.
Dr Richard F. Neville. Thanks, Joe, for your observations and questions as a leader in this particular field of interest. Only one sensor is required to obtain data from the entire graft. As a matter of fact, based on data accumulated to date, the software has been adjusted and can now supply information on flow from the inflow and outflow arterial beds not just the graft itself. What does the sensor actually measure? The signal generated is not solely deformation of the piezoelectric material. An acoustic frequency spectrum is constructed from signal data delivered with a proprietary parameter based on a compilation of sensor data. This parameter corresponds to the degree of stenosis and location of the stenosis. In terms of your question about graft failure, the graft-sensor device can generate an alert if flow has changed within the graft with a corresponding degree of stenosis. This self-monitoring graft can also generate an alert transmitted wirelessly to a remote location if the degree of stenosis has changed or is increasing in severity.
The system can store a wealth of data with a timeline, and part of the challenge will be to determine how to sift through all of these data and report on progression of a problem or occurrence of a hemodynamically critical problem prior to graft failure. The patient could then come in for evaluation by examination or further imaging. As you know, it is difficult to know when a graft will occlude, but hopefully, an intervention or at least imaging, prior to graft failure would result in continued graft performance, because once the graft occludes, revision is more difficult, and it is certainly easier to perform thrombectomy on a freshly thrombosed bypass graft or dialysis access graft than it is days or weeks later. The idea of this system is real-time, continuous self-monitoring to identify the failing graft prior to occlusion.
INVITED COMMENTARY
Ahmed M. Abou-Zamzam Jr, MD, Loma Linda, Calif
The search for the optimal arterial replacement has continued for decades. The avenues of focus have been on material, technique, and medical adjuncts. Simultaneously, the role of interventions to salvage failing grafts has been dominated by duplex ultrasound surveillance. Duplex surveillance has been driven by the idea that demonstrable changes in hemodynamics corresponding with impending graft failure can be detected and treated before graft thrombosis. Surveillance has suffered from the determination of the best intervals, and the role of surveillance of prosthetic grafts has not been as well-demonstrated as for vein grafts. Enter the authors of the current manuscript. In this paper, the authors have taken another tack to optimize graft performanceda self-monitoring graft. Grafts previously lost in the interval between scheduled surveillance may now be saved with real-time continuous in vivo monitoring. This, the authors hope, can improve outcomes with prosthetic grafts until the holy grail of a perfect arterial substitute is attained. This paper offers a proof-of-concept study demonstrating a self-monitoring prosthetic bypass graft. The authors have developed a piezo-electric sensor that can be implanted surrounding a polytetrafluoroethylene graft. This sensor can then remotely deliver information regarding flow dynamics in the graft in real time via Blue Tooth technology. This is accomplished using proprietary parameters based on the acoustic energy present in the system. The current manuscript demonstrates early in vitro testing as well as in vivo results in an ovine carotid-carotid bypass model with follow-up to 30 days. The sensor covers 2 cm of the 20-cm graft and was able to detect upstream and downstream stenoses in vitro. The in vivo testing demonstrated that the data can be easily collected on a daily basis through living tissue. However, the in vivo testing did not provide any information on detection of stenoses (likely owing to the short time frame).
This technology is exciting and has been ushered forward by the miniaturization that has been possible
